Diagnostics firm Avacta has announced that it has entered a non-exclusive distribution agreement with life sciences company Calibre Scientific for Avacta’s antigen lateral flow test, the AffiDX SARS-CoV-2.

The agreement covers the UK and European Economic Area (EEA) and means that the test will now be listed on Calibre Scientific’s website, where it will be available for purchase for professional use.

Avacta Group CEO Dr Alastair Smith said: “We are delighted that we have put in place this distribution agreement for the AffiDX SARS-CoV-2 antigen lateral flow test for professional use with Calibre.”

“As a high quality, global distributor of diagnostics and life science products with excellent links to our target markets, we are confident Calibre is well placed to support our penetration of the professional end use market in the UK and EEA. Avacta will continue to focus on developing direct sales opportunities to major corporates and other large scale end users.”

“Lateral flow tests have a crucial role to play in helping societies and the global economy return to normal and Avacta’s AffiDX antigen test, developed in the UK and based on UK technology is well placed to play a significant role in this process. I look forward to updating the market on progress over the coming months.”

Contact us


Tel: +44 (0)1424 777745

Fax: +44 (0)1424 777746



Kirkham Young Ltd.
The Old Court House
North Trade Road
East Sussex
TN33 0EX